Oncology Medical News about prostate cancer

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Does hormone treatment added to radiotherapy improve outcome in locally advanced prostate cancer?
Cancer, 06/04/09

Bria E et al. - In a trial to quantify the magnitude of benefit of the addition of hormone treatment (HT) to exclusive radiotherapy for locally advanced prostate cancer (PCa), it was found that hormone suppression plus radiotherapy significantly decreases recurrence and mortality of pts with localized PCa, without affecting toxicity.

Methods

Event-based relative risks (RR) with 95% confidence intervals (CIs) were derived through a random-effect model.
Differences in primary (biochemical failure and clinical progression-free survival) and secondary outcomes (cancer-specific survival, overall survival [OS], recurrence patterns, and toxicity) were explored.
Absolute differences and numbers of pts needed to treat (NNT) were calculated.
A heterogeneity test, a metaregression analysis with clinical predictors of outcome, and a correlation analysis for surrogate endpoints were also performed.

Results

7 trials (4387 pts) were gathered.
Hormone suppression significantly decreased both biochemical failure and clinical progression-free survival, with absolute differences of 10% and 7.7%, respectively, which translates into 10 and 13 NNT.
Cancer-specific survival and OS were also significantly improved by the addition of HT, without significant heterogeneity, with absolute differences of 5.5% and 4.9%, respectively, which translates into 18 and 20 NNT.
Local and distant relapse were significantly decreased by HT, by 36% and 28%, respectively, and no significant differences in toxicity were found.
Primary and secondary efficacy outcomes were significantly correlated.

<< Previous
Impaired interferon signaling is a common immune defect in human...

Next >>
Phase I clinical and pharmacokinetic study of the...